Roche carmotct 996 The CT-996 peptide represents a significant advancement in the development of oral treatments for obesity and type 2 diabetes. As a GLP-1 receptor agonist, CT-996 is designed to mimic the effects of the natural incretin hormone, glucagon-like peptide-1, playing a crucial role in regulating blood sugar levels and promoting satiety. Early clinical trials, particularly those conducted by Roche, have demonstrated promising results, showcasing the drug's potential for weight management and glycemic control. This investigational compound is being developed as a once-daily oral small molecule, offering a convenient alternative to injectable therapies.
CT-996 is a small-molecule GLP-1 receptor agonist that functions by activating the GLP-1 receptor. This activation leads to several beneficial effects, including increased insulin secretion, reduced glucagon secretion, slowed gastric emptying, and a diminished appetite, all of which contribute to better blood sugar control and weight loss. Initially developed by Carmot Therapeutics, CT-996 is now under the development umbrella of Roche, following their acquisition of Carmot. The drug is currently in early-phase clinical trials, with ongoing research focused on assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics. Evidence from Phase 1 studies indicates that CT-996 can induce significant weight loss within a short period, with participants experiencing a mean weight reduction of approximately 6.1% within four weeks of treatment2024年7月26日—The Visible Alpha GLP-1 Drug Monitor tracks the current and projected growth of the GLP-1 (glucagon-likepeptide...CT-996in Phase 2 and Phase 1 ....
The primary indications for CT-996 are obesity and type 2 diabetes (T2D). Its ability to promote weight loss and improve glycemic control makes it a compelling candidate for individuals struggling with these chronic conditionsRoche Continues to Reap Rewards of Carmot Buyout with .... Studies have shown that CT-996 can lead to both weight loss and improvements in insulin sensitivity, addressing key metabolic dysfunctions associated with T2D. Beyond initial weight reduction, researchers are also exploring CT-996's potential for long-term weight maintenance, which is a critical challenge in obesity management. The drug's oral administration offers a significant advantage in patient compliance and convenience compared to existing injectable GLP-1 receptor agonists.Wegovy rival to be part of a suite of weight loss drugs ...
CT-996 is progressing through clinical development, with ongoing studies in Phase 1 and moving towards Phase 2. These trials are crucial for establishing the drug's efficacy and safety profile in larger patient populations. Data from early trials have been met with optimism, highlighting the drug's well-tolerated nature, with most adverse events reported as mild to moderate. The development of CT-996 is part of a broader surge in interest and investment in GLP-1 receptor agonists, driven by the success of established medications like semaglutide.NCT05814107 | Phase 1 Study of CT-996 in Overweight/ ... Roche's commitment to advancing CT-996 underscores its potential to compete in this rapidly evolving therapeutic landscape作者：S Madsbad·2025·被引用次数：23—CT-996 is another small molecule, orally active-biased GLP-1 RA, which after 4 weeks treatment in a phase 1 study induced a mean weight loss of −7.3% compared .... The drug's distinct chemical scaffold is also noted for sharing similarities with other oral GLP-1 assets, suggesting a convergence of research efforts in this area.
While CT-996 shares the GLP-1 receptor agonist mechanism with other established and emerging treatments, its oral formulation and specific molecular design set it apart. Unlike many current GLP-1 RAs that are administered via injection, CT-996 offers the convenience of a daily pill2024年7月17日—Roche's oral GLP-1 receptor agonist CT-996—obtained in the .7 billion acquisition of Carmot Therapeutics—reduced body weight by more than 6% .... This oral accessibility is a significant differentiator, potentially broadening patient access and adherence.罗氏口服GLP-1R激动剂CT-996的I期研究结果积极，1个月减重 ... Furthermore, research suggests that CT-996 may possess a biased signaling profile, meaning it might preferentially activate certain downstream pathways of the GLP-1 receptor, potentially optimizing therapeutic benefits while minimizing certain side effects. This nuanced mechanism is a focus of ongoing research, aiming to refine the therapeutic window and efficacy of GLP-1-based treatments.
The CT-996 peptide is emerging as a highly promising investigational drug with the potential to significantly impact the treatment of obesity and type 2 diabetes.Roche reports positive data from Phase I obesity treatment trial Its development as an orally administered GLP-1 receptor agonist represents a crucial step forward, offering a convenient and effective option for patients. With promising early clinical data demonstrating efficacy in weight management and glycemic control, CT-996 is poised to become a key player in the future of metabolic disease treatment. Continued research and clinical trials will further elucidate its full therapeutic potential and solidify its place among the next generation of metabolic therapies.
Join the newsletter to receive news, updates, new products and freebies in your inbox.